Lucid Diagnostics (NASDAQ:LUCD) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research report report published on Wednesday,Benzinga reports. They currently have a $2.00 price target on the stock.

A number of other equities analysts have also recently commented on LUCD. Ascendiant Capital Markets decreased their target price on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating on the stock in a research report on Monday, December 9th. Needham & Company LLC raised their price objective on Lucid Diagnostics from $2.50 to $3.00 and gave the company a “buy” rating in a research note on Monday, March 24th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $3.40.

Lucid Diagnostics Stock Performance

LUCD stock opened at $1.58 on Wednesday. The company has a market capitalization of $93.76 million, a PE ratio of -1.39 and a beta of 1.34. Lucid Diagnostics has a one year low of $0.63 and a one year high of $1.63. The company’s 50 day moving average price is $1.27 and its two-hundred day moving average price is $1.01.

Institutional Investors Weigh In On Lucid Diagnostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LUCD. Sargent Investment Group LLC purchased a new position in shares of Lucid Diagnostics in the fourth quarter valued at about $442,000. Citadel Advisors LLC bought a new position in Lucid Diagnostics during the 4th quarter valued at approximately $98,000. Sunbelt Securities Inc. bought a new position in Lucid Diagnostics during the 4th quarter valued at approximately $67,000. Geode Capital Management LLC lifted its holdings in Lucid Diagnostics by 30.9% in the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock worth $229,000 after buying an additional 65,964 shares during the period. Finally, Lido Advisors LLC grew its position in shares of Lucid Diagnostics by 40.0% in the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after buying an additional 40,000 shares during the last quarter. 74.01% of the stock is currently owned by institutional investors.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.